Neutrophil function, nitric oxide, and blood oxidative stress in Parkinson's disease

Movement Disorders

Volumn 11, Issue 3, 1996, Pages 261-267

  Gatto, Emilia M ^a   Carreras, María C ^a   Pargament, Griselda A ^a   Riobo, Natalia A ^a   Reides, Claudia ^b   Repetto, Marisa ^b   Fernandez Pardal, Manuel M ^a   Llesuy, Susana ^b   Poderoso, Juan J ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Neutrophils; Nitric oxide; Parkinson's disease

Indexed keywords

CATALASE; HYDROGEN PEROXIDE; LEVODOPA; MARKER; NITRIC OXIDE; PHORBOL 13 ACETATE 12 MYRISTATE; RADICAL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; CHEMICAL INTERACTION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; MALE; NEUTROPHIL; NORMAL HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; STIMULATION;

ANTIPARKINSON AGENTS; CARBIDOPA; CATALASE; CHEMILUMINESCENT MEASUREMENTS; DRUG THERAPY, COMBINATION; ERYTHROCYTES; FEMALE; FREE RADICALS; HUMANS; HYDROGEN PEROXIDE; LEVODOPA; MALE; MIDDLE AGED; NEUTROPHILS; NITRIC OXIDE; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 0029933143     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110308     Document Type: Article

References (39)

1. Fahn S. Parkinsonism. In: Wyngaarden JB, Smith LH Jr, eds. Cecil's textbook of medicine. Philadelphia: Saunders, 1988:2143-2147.
2. Jenner P, Dexter DT, Shapira AHV, Marsden CD. Free radicals involvement and altered iron metabolism as a cause of Parkinson's disease. In: Marsden CD, Fahn S, eds. The assessment and therapy of parkinsonism. New Delhi, NJ: Parthenon, 1990:17-80. (New Trends in Clin Neurol)
3. Hubble JP, Cao T, Hassanein RES, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 1993; 43:1693-1697.
4. Tanner CM, Langsten JW. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 1990;40(3 suppl):17S-30S.
5. Fahn S. The endogenous toxic hypothesis of the etiology of Parkinson's disease and a pilot trial of high dosage antioxidants in an attempt to slow the progression of the illness. Ann NY Acad Sci 1989;570:186-196.
6. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra. An HPLC and ESR study. Mov Disord 1994;9:92-97.
7. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease. Evidence supporting it. Ann Neurol 1992;32: 804-812.
8. Schapira AHV. Evidence for mitochondrial dysfunction in Parkinson's disease. A critical appraisal. Mov Disord 1994; 9:125-138.
9. Dexter DT, Carayon M, Vidailhet M, et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 1990;55:16-20.
10. Dawson TM, Dawson VL, Snyder SH. A novel neuronal messenger molecule in brain: the free radical nitric oxide. Ann Neurol 1992;32:297-311.
11. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhidryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991;266:4244-4250.
12. Parker WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989;26:719-723.
13. Ney P, Schroder H, Schror K. Nitrovasodilator-induced inhibition of LTB4 release from human PMN may be mediated by cyclic GMP. Eicosanoids 1990;3:243-245.
14. Carreras MC, Pargament GA, Catz SD, Poderoso JJ, Boveris A. Kinetics of nitric oxide and hydrogen peroxide production and formation of peroxynitrite during the respiratory burst of human neutrophils. FEBS Lett 1994;341:65-68.
15. Kalra J, Rajput AH, Mantha SV, Chaudhanry AK, Prasad K. Oxygen free radicals producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease. Mol Cell Biochem 1992;112:181-186.
16. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
17. Markert M, Andrews PC, Babior BM. Measurement of production by human neutrophils. The preparation and assay of NADPH oxidase-containing particle from human neutrophils. Methods Enzymol 1984;105:358-361.
18. Hyslop PA, Sklar LA. A quantitative fluorometric assay for the determination of oxidant production by polymorphonuclear leukocytes: its use in the simultaneous fluorometric assay of cellular activation processes. Anal Biochem 1984; 141:280-286.
19. Murphy ME, Sies H. Reversible conversion of nitroxyl anion to nitric oxide superoxide dismutase. Proc Natl Acad Sci USA 1991;88:10860-10864.
20. Winterbourn CC. Oxidative reactions of hemoglobin. Methods Enzymol 1990;186:265-272.
21. Brestel EP. Co-oxidation of luminol by hypoclorite and hydrogen peroxide. Implications for neutrophil chemiluminescence. Biochem Biophys Res Commun 1985;126:482-488.
22. Misra HD, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972;217:3170-3179.
23. Chance B. Special methods: catalase. In: Glick D, ed. Methods of biochemical analysis. New York: Interscience, 1954: 408-424.
24. Lowry OH, Roseborough A, Fan AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
25. Lissi E, Pascual C, Del Castillo M. Luminol luminescence induced by 2,2-azo-bis (2-amidinopropane) thermolysis. Free Rad Res Comms 1992;17:299-311.
26. Crosby WH, Munn JI, Furth FW. Standardizing a method for clinical hemoglobinometry. US Armed Forces Med J 1954;5:693.
27. Hoehn MM, Yahr MD. Parkisonism: onset, progression and mortality. Neurology 1967;17:427-442.
28. Cleeter MWJ, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AHV. Reversible inhibition of cytochrome C oxidase, the terminal enzyme of the mitochondrial respiratory brain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett 1994;345:50-54.
29. Youdim MBH, Ben-Sachar D, Eshel G, Finberg JPM, Riederer P. The neurotoxicity of iron and nitric oxide, relevance to the etiology of Parkinson's disease. Adv Neurol 1993;60:259-266.
30. Nisbet AP, Foster OJF, Kinsbury A, Lees AJ, Marsden CD. Nitric oxide synthase mRNA expression in human subthalamic nucleus, stratum and globus pallidus: implications for basal ganglia function. Mol Brain Res 1994;22:329-332.
31. Schapira AVH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;i:1269.
32. Spencer Smith T, Parker WD Jr, Bennet JP Jr. L-DOPA increases nigral production of hydroxyl radicals in vivo: Potential L-DOPA toxicity. Neuroreport 1994;5:1009-1011.
33. Radi R, Cosgrove TP, Beckman JS, Freeman BA. Peroxynitrite-induced luminol chemiluminescence. Biochem J 1993; 290:52-57.
34. Van der Vliet A, Smith D, O'Neill CA, et al. Interactions of peroxynitrite with human plasma and its constituents: oxidative damage and antioxidant depiction. Biochem J 1994; 303:295-301.
35. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989;53:692-697.
36. 2. Arch Biochem Biophys 1981;212:411-416.
37. Fernandes MAS, Santana I, Januario C, Cunha L, Oliveira CR. Decreased superoxide dismutase activity in erythrocytes from patients with Alzheimer's disease. Med Sci Res 1993;21:679-682.
38. Nakashima K, Watanabe Y, Kuno N, Nanba E, Takahashi K. Abnormality of Cu/Zn superoxide dismutase (SOD1) activity in Japanese familial amyotrophic lateral sclerosis with two base pair deletion in the SOD1 gene. Neurology 1995; 45:1019-1020.
39. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brain. J Neurochem 1989;52:515-520.